Jing Li, PhD, Robert Tyler Braun, PhD, Sophia Kakarala, and Holly G. Prigerson, PhD
For dying patients and their loved ones to make informed decisions, physicians must share adequate information about prognoses, prospective benefits and harms of specific interventions, and costs.
AMA J Ethics. 2022;24(11):E1040-1048. doi:
10.1001/amajethics.2022.1040.
Fragmentation in US health care delivery streams and shortcomings in formal quality measures mean that transparency could be more useful to policymakers and regulators than patients.
AMA J Ethics. 2022;24(11):E1075-1082. doi:
10.1001/amajethics.2022.1075.
Sarosh Nagar, Leah Z. Rand, PhD, and Aaron S. Kesselheim, MD, JD, MPH
This article analyzes differences in prescription drug pricing transparency practices among 3 Organisation of Economic Co-operation and Development member nations.
AMA J Ethics. 2022;24(11):E1083-1090. doi:
10.1001/amajethics.2022.1083.
Dr Chloë G. K. Atkins joins Ethics Talk to discuss her article, coauthored with Dr Sunit Das: “What Should Clinicians and Patients Know About the Clinical Gaze, Disability, and Iatrogenic Harm When Making Decisions?”
Clinicians in Catholic health care institutions cannot prescribe contraceptives for pregnancy prevention under a false diagnosis without committing fraud and contravening doctrine. Referrals are one option the authors consider for navigating patient requests for contraception.
AMA J Ethics. 2018;20(7):E630-636. doi:
10.1001/amajethics.2018.630.